Li Li

Li Li possesses extensive experience in the pharmaceutical and academic sectors, having held leadership roles at Merck from April 2022 to August 2024, including Executive Director and Senior Director of SSF PDMB-DMPK. Prior to Merck, Li Li worked at Amgen Inc from September 2008 to September 2019, where responsibilities included Senior Scientist in immuno-oncology and liver disease. Li Li's career began with a postdoctoral position at the University of Pennsylvania from April 2004 to September 2008. An academic foundation is established with a PhD in Immunology from Lund University, Sweden, and an MSc in Clinical Virology from Peking University Health Science Center.